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Abstract
The complexity of the treatment of tissue lesions, particularly bone lesions, in regenerative medicine 
depends on the origin of the substance loss (traumatic, tumoral, infectious, etc.), its size and 
mechanical requirements. In the field of dental surgery, the need to ensure rapid regeneration of 
injured bone tissue for periodontal, post-extractional or pre-implant corrective surgery leads dental 
surgeons to have a large number of biomaterials in their therapeutic arsenal. The mineral materials 
are most often used because of their chemical composition which is close to bone’s mineral phase. 
They also present a resorption time in agreement with the time of formation of new bone.
However their benefits are inconstant and the need of new bioactive structures, well accepted by 
the host, and favoring tissue healing has grown. Here is the place for platelet concentrates such as 
Platelet Rich Plasma (PRP) and Platelet Rich Fibrin (PRF) which are rich in growth factors, cytokines 
and others proteins. PRF became the most commonly used in the last decade as it is easier to handle 
with its polymerized form which mimics an extracellular matrix favorable to cell proliferation and 
differentiation. A new option, called platelet lysate, has recently been highlighted in the general field 
of tissue regeneration and has the advantage of making platelet’s content directly available. Proteins 
concentrations are increased in these products even if their liquid form complicates their use in daily 
practice. This mini-review sums up the main clinical interests for the use of platelet concentrates and 
the new perspectives in the field of alveolar bone regeneration especially with platelet lysate.
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Introduction
Blood-derived materials constitute a family of biomaterials designed from blood components 
and extracted from patient samples. They may concern only one molecule as is the case of albumin 
[1] and immunoglobulins [2], or a whole part of the blood sample combining the different elements 
including cells [3]. The samples may be autologous for an implantation in the same subject or may 
come from different individuals or even species, provided that the samples do not contain pathogens 
that would be transmitted. Blood richness in cellular and protein elements offer perspectives in the 
treatment of pathologies for which healing processes are deficient. Indeed, the presence of elements 
such as growth factors and cytokines can re-initiate healing pathways by modifying the activity of 
cells responsible for tissue regeneration.
In the field of dentistry, a wide variety of hard and soft tissues can be affected by acute or chronic 
destructive diseases. More than dental enamel and dentine which can be affected by caries [4], 
alveolar bone can be destroyed in periodontitis [5] or periapical infections [6], and the gingival 
level reduced in periodontitis conditions as well. Cell competition from different tissues to occupy 
the site to be healed [7], as well as the presence of large numbers of bacteria [8,9] on a complex and 
weakened immune field [9], complicates scarring processes. The latter must therefore be clinically 
re launched and the dental surgeon has at his disposal several biomaterials to graft in affected 
defects [10]. Mineralized biomaterials called bone substitutes may help to enhance alveolar bone 
volume but results are inconstant and patient dependent [10-12], so here is the place for the use of 
platelet concentrates, a family of blood-derived materials for transplantation in patients. The first 
were described in the early 1970’s but main advances in their preparation and applications were 
published in the late 1990’s [13].
Thus, the objective of this mini-review is to present actual main clinical interests for the use of 
platelet concentrates and the new perspectives in the field of alveolar bone regeneration.
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Platelets in coagulation pathways
Platelets, also called thrombocytes, are nucleus-free cells resulting 
from megakaryocyte fragmentation in bone marrow and involved 
in the phenomena of coagulation [14]. The molecular, cellular and 
tissue mechanisms recruited during a vascular breach are complex. 
Briefly, to sum up the implication of fibrinogen and fibrin, when 
a blood vessel wall is broken, a contact appears between its outer 
layer and blood, then one molecule in particular, called Tissue 
Factor (TF), binds blood factor VII and activates it. A complex is 
thus formed between the TF and the newly created factor VIIa ("a" 
for "activated") [15]. This complex activates the factors IX and X 
present on cell membranes, which corresponds to the initiation of 
the exogenous pathway of coagulation [16-18]. Factor Xa binds to 
factor Va (activated elsewhere). This causes the platelet wall factors II 
and X to be activated in turn. Factor IIa appears: it is called thrombin. 
It has the role among others to ensure the conversion of fibrinogen 
(soluble, 450 Ångstrom, molecular weight 350 kDa [19]) to fibrin 
(insoluble) [20,21] by cleaving N-terminal ends of the Aα and Bβ 
chains of fibrinogen [19]. This allows the release of fibrin monomers 
and short peptides called fibrin peptides A and B. An association 
occurs between the newly revealed N-terminal ends on the monomers 
with the neighboring sequences of the others monomers [22,23]: 
there is formation of a fibrin polymer. Thrombin also activates the 
factor XIII, activation that occurs under the influence of calcium 
whose presence is essential for pro-coagulant complexes formation 
and thrombin generation [24]. Factor XIIIa is a transglutaminase 
type enzyme whose roles are to create covalent bonds between the γ 
chains of several monomers, to create also covalent bonds between 
the α chains of several monomers and to link the newly formed clot 
with sub endothelial proteins. All these pathways among the whole 
process of coagulation lead to clot stabilization [15,25]. A brief sum 
up of mechanisms involving fibrin is presented on Figure 1.
PRP and PRF in oral surgery
Blood circulating platelets are thus mainly involved in the 
whole process of coagulation and represent an essential target in 
biomedicine. In this way, they can be easily isolated from blood 
samples on citrated tubes and grouped together in products called 
Platelet Concentrates (PC) that are suitable for clinical use. This 
PC family especially includes, among others, liquid plasma called 
Platelet Rich Plasma (PRP) [26] and a fibrin clot formed in absence 
of anticoagulant called Platelet Rich Fibrin (PRF) [27]. They contain 
the sample’s platelets and a majority of the white cells [26]. Before 
using them in various biomedical applications, it is possible to ensure 
that the platelet derivative will no longer contain any pathogens [28], 
that might have colonized it in the event of contamination [29], with 
a phase of leucocyte depletion by filtration or other mechanisms such 
as irradiation. Techniques for the preparation of platelet concentrates 
are numerous [28], many institutions having designed their own 
protocol with high levels of efficiency and a good reproducibility of 
results [30-32]. The PRP isolation method (Figure 2) consists in a two-
step gradient centrifugation of a mix containing whole blood and an 
anticoagulant (e.g. acid citrate dextrose). The first centrifugation (soft 
spin 3000 g, 10 min) results in a leuko reduced platelet-rich plasma 
supernatant and red blood cells. Then, the second centrifugation 
(hard spin between 6000 and 10000 g, 30 min) is performed to isolate 
residual erythrocytes at the bottom and two other phases: Platelet 
Poor Plasma (PPP) at the top and Platelet Rich Plasma (PRP) in the 
middle [26]. The objective is to concentrate the platelet pellet into a 
small amount of plasma volume [33].
In the case of PRF, the main protocol works with low speed 
centrifugation (3000 g, 10 min) immediately after blood sampling 
without the use of anticoagulants additives [27,34]. PRF clot appears 
in the middle of the tube (Figure 3) between platelet poor plasma and 
red blood cell pellet [27] (Figure 3).
These two P Care growth factors and cytokines rich like 
VEGF (Vascular Endothelium Growth Factor), PDGF (Platelet-
Derived Growth Factor), EGF (Epidermal Growth Factor) or 
TGF-β (Transforming Growth Factor-beta) [26]. These molecules 
contributing to involve tissue growing and organ development, it 
constitutes an important argument for biomedical assays of platelet 
concentrates [28]. Main applications concern wound healing and 
musculoskeletal diseases [3] especially in the field of oral surgery, in 
which the practitioner has to deal with several diseases on alveolar 
bone and others various tissues, the whole in an infected environment. 
Figure 1: Coagulation pathways involving fibrin and resulting in clot 
stabilization. Proaccelerin, also called labile factor (noted factor V), binds with 
Stuart factor (X) to form a complex activating both molecules (Va and Xa). 
Together, they allow formation of thrombin (IIa) from pro-thrombin (II), the 
new molecule which plays a dual role of transforming fibrinogen molecules 
into fibrin monomers and activating fibrin stabilizing factor (XIIIa). This one, 
as its name indicates, allows the stabilization of fibrin polymers constructed 
from fibrin monomers previously formed.
Figure 2: Main method for PRP preparation. After blood sampling and 
addition of an anticoagulant, a low speed centrifugation (3000 g, 10 min) is 
performed. Red blood cells are excluded and then a second centrifugation 
(high speed, between 6000 and 10000 g, 30 min) is applied. It separates 
platelet rich plasma (PRP) from Platelet Poor Plasma (PPP) and red cells.
Figure 3: Main method for PRF preparation. Immediately after blood 
sampling, a low speed centrifugation (3000 rpm, 10 min) is performed without 
addition of an anticoagulant. It separates platelet rich fibrin clot (PRF) from 
Platelet Poor Plasma (PPP) and red cells.
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Oral surgical procedures concern tooth extractions, implantology 
and period ontology, i.e. hard and soft tissue management in healthy 
or pathologic situations. In a healthy patient, buccal wound would 
heal thanks to the presence of a simple clot, rich in platelets. However, 
in some diseases healing process is not efficient. In periodontitis, 
aggressive bacteria have colonized periodontal tissues and lead to 
tissue destruction [5]. The process has to be stopped by bacteria 
elimination but when tissue defect is too important a biomaterial 
graft may become necessary to help bone regeneration and volume 
reconstruction. In bisphosphonate-related osteonecrosis of the 
jaw, bisphosphonate inhibit osteoclasts functions, especially their 
angiogenic ability [35], and lead to bone necrosis in case of a trauma 
[36]. In these two examples, wound process has to be re-initiated so 
here is the main argument favoring the use of platelet concentrates, 
rich in growth factors, as therapeutic or even preventive materials. 
In the 2000’s, before the increase for interest on PRF, PRP was the 
main PC to be used in dentistry for bone regeneration in extraction 
sockets and also in association with other biomaterials for periodontal 
treatments [37]. It presents the advantage of concentrating a high 
quantity of autologous platelets in a small volume of plasma but such 
a liquid is difficult to handle [37]. A mix of PRP with calcium chloride 
and thrombin leads to platelet activation, growth factors release and 
material gelation which become easier to manipulate [38].
When the protocol to produce PRF was described it enabled 
to directly obtain a gelled platelet concentrate with a unique 
centrifugation of blood sample [34]. Extra-cellular fibrin has 
polymerized and constituted a tri-dimensional network. Procedure 
is very simple and no additive agent is necessary to make PRF so 
the method began to expand in dental practice and gradually over 
passed PRP in oral surgery [13]. PRF has various properties on 
cells and tissues, for example it has already been shown that it was 
able to promote angiogenesis, mitogenesis or cell migration [13]. 
However PRF and PRP content are very similar and the difference 
essentially resides on their consistence. Indications between the two 
are quite similar, from post-extraction socket filling [39] to guided 
bone regeneration and soft tissue management [13]. For example, 
in case of teeth extractions on a patient suffering from a hereditary 
osteogenesis imperfect, it helps to guide healing process. The patient 
was treated with intravenous bisphosphonates for about twenty years 
and stopped her treatment more than ten years ago. She already had 
previous extractions after this treatment and developed each time an 
alveolitis. The day of the extraction of teeth number 15 and 16 (Figure 
4), a PRF technic was used. The blood sample was centrifuged during 
the surgery and the PRF clot (Figure 5) was set up into bone socket 
(Figure 6). Sutures must be performed in order to maintain the clot 
under the gum and over the bone to heal (Figure 7). Thanks to this 
technic; the patient’s cells are guided in the fiber network in presence 
of all growth factors. After 2 and 3 weeks (Figures 8,9) final healing 
was satisfying without any complications; soft tissue maturation was 
optimal.
A wide perspective from platelet concentrates to platelet 
lysate
Platelet Lysate (PL) corresponds to platelet’s cytoplasm content 
recovered after destruction of the plasma membrane. Growth 
factors, fibrinogen molecules, cytokines and other proteins become 
released and directly accessible. To generate platelet lysate, different 
methods exists: a thrombin supplementation to initiate thrombocyte 
degranulation, PC sonication or a frozen sequence to lyse cell 
membranes [28]. None separation is necessary before protein use, 
Figure 4: Pre-surgical photography. Teeth number 15 and 16 need to be 
extracted.
Figure 5: Platelet Rich Fibrin clot obtained after centrifugation and ready to 
be grafted in extraction sockets.
Figure 6: PRF clot is carefully set up into extraction sockets to avoid its 
fragmentation.
Figure 7: Final sutures must fix vestibular and palatal gum in order to 
stabilize PRF and blood clots over alveolar bone.
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even if a new centrifugation (1400g, 10min) is possible to eliminate 
cell debris [40]. Fibrin for example, which is already found in platelet 
concentrates before cell lysing, sees its concentration growing in 
the lysate. Several platelet lysates obtained from different subjects 
may then be pooled to grow available quantities before biomedical 
applications [28] and to optimize the lysate quality. Indeed, it has been 
shown that the PL’s properties on cell proliferation and osteoblastic 
differentiation were higher with a sample obtained from a younger 
donor [41]. These pooled human Platelet Lysates (hPL) does not 
present any risk of immune rejection or pathogen transmission due 
to filtrations and treatments they have received during their creation 
protocol.
It is already used routinely in-vitro for cell culture medium’s 
supplement [42], especially for cells to be grafted in human because, 
unlike Fetal Bovine Serum, it has the advantage of being autologous 
or allogeneic. In the field of dentistry, even if platelet concentrates 
such as PRP or PRF are currently used for oral surgery, platelet lysate 
has not been validated yet for a clinical use. Several human studies 
have already been performed for others biomedical applications, 
trying to apply PLcutaneous and tissue wounds [27,43] or mucositis 
[44]. Results on soft tissues are nuanced in comparison with others 
PC but the main difference in PL is the higher availability of growth 
factors and other proteins after cell lysis so the expected benefits 
in bone regeneration are significant. Indeed, when platelet lysate, 
with its high content in fibrinogen, is associated with coagulation 
promoters - such as calcium chloride - to create a three dimensional 
hydrogel [45], it is supposed to generate a PRF-like network with 
higher availability for growth factors. Inside this structure, human 
cells would survive and proliferate optimally [46] thanks to the high 
PL’s biocompatibility. However, fibrin network may be degraded 
too fast [47] and does not present a high resistance to mechanical 
stress. Associations with other biomaterials should be further studied, 
especially mineralized bone substitutes (hydroxyapatites, tri-calcium 
phosphates…), because, even if the benefits on tissue resorption and 
formation does not seems to be increased [48-50], it would improve 
the material resistance. Moreover, regenerative therapies must be 
designed to optimize the potential of surrounding cells, especially in 
dentistry where the use of cell-graft is restricted. The main limits are 
put by regulatory frameworks that restrict in many countries the use 
of exogenous cells and growth factors for human therapy, especially 
in the context of pathologies with low morbidity. Here is an advantage 
for the use of autologous platelet lysates, a bioactive structure which 
would perfectly meet the objective of graft colonization by blood 
vessels and host’s cells [45,51-53].
Conclusion
With the development of platelet concentrates use in all fields of 
research, the new trend is to study platelet lysate, which is no more 
complex to obtain than PRP and PRF. Its clinical indications have 
yet to be clearly defined in large-scale trials, but its in vitro benefits, 
particularly for cell culture, are now well known. The future for the 
use of this platelet derivative may resides on the treatment of various 
diseases assimilated to chronic scarring defects because preliminary 
results on soft tissues are promising.
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